Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Disappointing phase III preliminary results for CeaVac in colorectal cancer

Dec. 16, 2002

IDEC-114 reported safe and effective in refractory follicular lymphoma

Dec. 16, 2002

Minimal toxicity reported for SGN-30 in Hodgkin's disease and lymphoma

Dec. 13, 2002

MDX-060 has marked antitumor activity in CD30+ lymphoma-bearing mice

Dec. 11, 2002

Vasogen reports preliminary results from pilot study in CLL

Dec. 11, 2002

Good safety profile reported for IL-13-PE38QQR in malignant glioma

Dec. 10, 2002

Dendreon announces amended pivotal trial for Provenge prostate cancer vaccine

Dec. 9, 2002

Promising data reported for dendritic cell vaccine in GBM

Dec. 5, 2002

Potential use of TP-38 in recurrent malignant brain tumors

Dec. 4, 2002

Antitumor efficacy of EMD-273063 alone or combined with IL-2

Nov. 29, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...